The BRAF mutation rate in patients is approximately 41–55%.[2] However, BRAF inhibitors, such as Dabrafenib and Trametinib (D+T), as well as immune checkpoint inhibitors (ICIs) targeting CTLA‐4 and PD‐1/PD‐L1, have not yielded optimistic outcomes in melanoma patients.[3, 4] Therefore, the exploration of additional therapeutic approaches and the development of improved combination treatments are essential for improving patient prognosis. This evidence concerns the gene BRAF and melanoma.